From Interview #105
With Jim St. Clair and James Fargason
Digital twins are emerging as one of the most powerful tools to reduce uncertainty in medicine, particularly in oncology, where clinicians are often forced to make high-stakes decisions with incomplete data. In this full interview, Jim St. Clair and James Fargason explore how digital twin technology could fundamentally reshape healthcare by creating dynamic, data-driven virtual representations of patients that evolve in real time.
Drawing on advances from engineering, infrastructure, and aerospace, the conversation examines how patient-centric digital twins could integrate genomics, pharmacogenomics, environmental exposure, clinical history, and real-world data to improve treatment selection, reduce toxicity, and accelerate clinical trials. The discussion highlights why digital twins go beyond static AI predictions, emphasizing continuous feedback, simulation, and probability modeling.
The guests also address critical challenges, including data fragmentation, ownership, trust, and clinician adoption. As healthcare moves toward precision medicine and value-based care, digital twins may become indispensable tools for clinicians, researchers, and patients seeking more personalized, evidence-driven decisions.
From Interview #104
With Samara Barend
Medical-grade wearables are rapidly moving beyond wellness tracking and becoming essential tools in cancer care. In this episode, Samara Barend, CEO of AION Biosystems, joins leading oncology clinicians to explain how continuous, longitudinal patient data is reshaping early detection, treatment tolerance, and emergency prevention. Barend shares the development story behind TempShield, the first FDA-cleared long-term wearable designed to identify infection risk before it becomes life-threatening. The discussion explores how continuous temperature monitoring reduces preventable hospitalizations, why certain signals offer higher clinical value than others, and how providers can integrate these devices without overwhelming clinical workflows. The conversation also addresses interoperability, reimbursement, alert fatigue, and the shift toward simulation-driven precision medicine.
From Interview #103
With Dr. Chadi Nabhan
In this thought-provoking episode, Dr. Chadi Nabhan joins a roundtable with Drs. Sanjay Jani, Douglas Flora, and Debra Patt to examine how AI is transforming oncology. Once dominated by the traditional “cut, poison, burn” approach, cancer care is undergoing a shift driven by precision tools, targeted therapies, and intelligent systems. Dr. Nabhan, a seasoned oncologist and prolific author, shares insights from his latest book and underscores the need for scalable education on emerging technologies. The conversation covers everything from digital pathology and drug development to patient communication and the emotional toll of missed timing in treatment. This episode offers a rich blend of clinical depth and personal reflection—an essential listen for healthcare professionals navigating cancer's new digital frontier.
From Interview #102
With Mika Newton
In this roundtable episode from Tensor Black, Dr. Doug Flora joins co-hosts Dr. Sanjay Juneja, Debra Patt, and Mika Newton to explore how artificial intelligence is disrupting U.S. healthcare policy, oncology practice, and digital health innovation. Dr. Flora, Executive Medical Director of Oncology Services at St. Elizabeth Healthcare and Editor-in-Chief of *AI in Precision Oncology*, offers candid insights on change management, clinical decision support, and value-based care. The panel also dissects major themes from the Health conference, Medicare’s AI-driven authorization model, and how AI tools like chart summarization can reshape patient access and clinical efficiency. This discussion, designed for healthcare executives and oncology leaders, highlights how AI is not only augmenting decisions but demanding new strategies for adoption, reimbursement, and scale.
